Travere Therapeutics Inc (NASDAQ: TVTX) stock closed at $10.98 on 9/6/24 after a major increase of 10.6%. Moreover, this advance was accompanied by exceptionally high trading volume at 686% of normal. The stock has risen 21.6% during the last week and has performed in line with the market over the last nine months.
Current PriceTarget Research Rating
TVTX’s future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to continue to be Value Creation neutral.
Travere Therapeutics has a current Value Trend Rating of D (Negative). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Travere Therapeutics has a very low Appreciation Score of 8 but a slightly positive Power Rating of 64, producing the Negative Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment